{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:09Z","timestamp":1794047469120,"version":"4.8.0"},"reference-count":48,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Innovative therapeutic strategies have emerged over the past decade to improve outcomes for most lymphoma patients. Nevertheless, the aggressive presentation seen in high-risk mantle cell lymphoma (MCL) patients remains an unmet medical need. The highly proliferative cells that characterize these tumors depend on nucleotide synthesis to ensure high DNA replication and RNA synthesis. To take advantage of this vulnerability, STP-B, a clinically available small molecule selectively targeting CTP synthase 1 (CTPS1) has been recently developed. CTPS1 is a key enzyme of the pyrimidine synthesis pathway mediated through its unique ability to provide enough CTP in highly proliferating cells. Herein, we demonstrated that CTPS1 was expressed in all MCL cells, and that its high expression was associated with unfavorable outcomes for patients treated with chemotherapy. Using aggressive MCL models characterized by blastoid morphology, TP53 mutation or polyresistance to targeted therapies, we showed that STP-B was highly effective at nanomolar concentrations in vitro and in vivo, irrespective of these high-risk features. Inhibition of CTPS1 rapidly leads to cell cycle arrest in early S-phase accompanied by inhibition of translation, including of the anti-apoptotic protein MCL1. Consequently, CTPS1 inhibition induced synergistic cell death in combination with the selective BCL2 inhibitor venetoclax, both in vitro and in vivo. Overall, our study identified CTPS1 as a promising target for MCL patients and provided a mechanism-based combination with the BCL2 inhibitor venetoclax for the design of future chemotherapy-free treatment regimens to overcome resistance.<\/jats:p>","DOI":"10.3324\/haematol.2023.284345","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T04:29:35Z","timestamp":1708576175000},"page":"2574-2584","source":"Crossref","is-referenced-by-count":4,"title":["Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma"],"prefix":"10.3324","volume":"109","author":[{"given":"Romane","family":"Durand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bellanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kervo\u00eblen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Dousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Menoret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Asnagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Pellat-Deceunynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"64574","doi-asserted-by":"crossref","unstructured":"Zhong L, Li Y, Xiong L. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021; 6(1):201.","DOI":"10.1038\/s41392-021-00572-w"},{"key":"64575","doi-asserted-by":"crossref","unstructured":"Wang ML, Jurczak W, Jerkeman M. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022; 386(26):2482-2494.","DOI":"10.1056\/NEJMoa2201817"},{"key":"64576","doi-asserted-by":"crossref","unstructured":"Dreyling M, Doorduijn JK, Gine E. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the european MCL network. Blood. 2022; 140(Suppl 1):1-3.","DOI":"10.1182\/blood-2022-163018"},{"key":"64577","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Morschhauser F, Chiron D. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial. Blood. 2021; 137(7):877-887.","DOI":"10.1182\/blood.2020008727"},{"key":"64578","doi-asserted-by":"crossref","unstructured":"Eichhorst B, Niemann CU, Kater AP. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023; 388(19):1739-1754.","DOI":"10.1056\/NEJMoa2213093"},{"key":"64579","doi-asserted-by":"crossref","unstructured":"Zhao S, Kanagal-Shamanna R, Navsaria L. Efficacy of Venetoclax in high risk relapsed mantle cell lymphoma (MCL)-outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020; 95(6):623-629.","DOI":"10.1002\/ajh.25796"},{"key":"64580","doi-asserted-by":"crossref","unstructured":"Martin P, Maddocks K, Leonard JP. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016; 127(12):1559-1563.","DOI":"10.1182\/blood-2015-10-673145"},{"key":"64581","doi-asserted-by":"crossref","unstructured":"Scheubeck G, Jiang L, Hermine O. Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia. 2023; 37(9):1887-1894.","DOI":"10.1038\/s41375-023-01977-y"},{"key":"64582","doi-asserted-by":"crossref","unstructured":"Huang Z, Chavda VP, Bezbaruah R, Dhamne H, Yang D-H, Zhao H-B. CAR T-cell therapy for the management of mantle cell lymphoma. Mol Cancer. 2023; 22(1):67.","DOI":"10.1186\/s12943-023-01755-5"},{"key":"64583","doi-asserted-by":"crossref","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017; 168(4):657-669.","DOI":"10.1016\/j.cell.2016.12.039"},{"key":"64584","doi-asserted-by":"crossref","unstructured":"Tisi MC, Moia R, Patti C. Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL. Blood Adv. 2023; 7(15):3916-3924.","DOI":"10.1182\/bloodadvances.2023009744"},{"key":"64585","doi-asserted-by":"crossref","unstructured":"Hermine O, Jiang L, Walewski J. High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2023; 41(3):479-484.","DOI":"10.1200\/JCO.22.01780"},{"key":"64586","doi-asserted-by":"crossref","unstructured":"Lynch EM, Hicks DR, Shepherd M. Human CTP synthase filament structure reveals the active enzyme conformation. Nat Struct Mol Biol. 2017; 24(6):507-514.","DOI":"10.1038\/nsmb.3407"},{"key":"64587","doi-asserted-by":"crossref","unstructured":"Van Kuilenburg ABP, Meinsma R, Vreken P, Waterham HR, Van Gennip AH. Identification of a cDNA encoding an isoform of human CTP synthetase. Biochim Biophys Acta. 2000; 1492(2-3):548-552.","DOI":"10.1016\/S0167-4781(00)00141-X"},{"key":"64588","doi-asserted-by":"crossref","unstructured":"Schimmel KJM, Gelderblom H, Guchelaar HJ. Cyclopentenyl cytosine (CPEC): an overview of its in vitro and in vivo activity. Curr Cancer Drug Targets. 2007; 7(5):504-509.","DOI":"10.2174\/156800907781386579"},{"key":"64589","doi-asserted-by":"crossref","unstructured":"Williams JC, Kizaki H, Weber G, Morris HP. Increased CTP synthetase activity in cancer cells. Nature. 1978; 271(5640):71-73.","DOI":"10.1038\/271071a0"},{"key":"64590","doi-asserted-by":"crossref","unstructured":"Martin E, Palmic N, Sanquer S. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature. 2014; 510(7504):288-292.","DOI":"10.1038\/nature13386"},{"key":"64591","doi-asserted-by":"crossref","unstructured":"Martin E, Minet N, Boschat A-C. Impaired lymphocyte function and differentiation in CTPS1-deficient patients result from a hypomorphic homozygous mutation. JCI Insight. 2020; 5(5):e133880.","DOI":"10.1172\/jci.insight.133880"},{"key":"64592","doi-asserted-by":"crossref","unstructured":"Minet N, Boschat A-C, Lane R. Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation. Life Sci Alliance. 2023; 6(9):e202302066.","DOI":"10.26508\/lsa.202302066"},{"key":"64593","doi-asserted-by":"crossref","unstructured":"Lin Y, Zhang J, Li Y. CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1. J Transl Med. 2022; 20(1):1-15.","DOI":"10.1186\/s12967-021-03206-5"},{"key":"64594","doi-asserted-by":"crossref","unstructured":"Liang J, Ren Y, Du K. MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma. Br J Haematol. 2023; 202(3):550-565.","DOI":"10.1111\/bjh.18878"},{"key":"64595","doi-asserted-by":"crossref","unstructured":"Wu F, Mao Y, Ma T. CTPS1 inhibition suppresses proliferation and migration in colorectal cancer cells. Cell Cycle. 2022; 21(24):2563-2574.","DOI":"10.1080\/15384101.2022.2105084"},{"key":"64596","doi-asserted-by":"crossref","unstructured":"Sun Z, Zhang Z, Wang Q-Q, Liu J-L. Combined inactivation of CTPS1 and ATR is synthetically lethal to MYC-overexpressing cancer cells. Cancer Res. 2022; 82(6):1013-1024.","DOI":"10.1158\/0008-5472.CAN-21-1707"},{"key":"64597","doi-asserted-by":"crossref","unstructured":"Asnagli H, Minet N, Pfeiffer C. CTP synthase 1 is a novel therapeutic target in lymphoma. Hemasphere. 2023; 7(4):e864.","DOI":"10.1097\/HS9.0000000000000864"},{"key":"64598","doi-asserted-by":"crossref","unstructured":"Ma\u00efga S, Brosseau C, Descamps G. A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines. Cytometry. 2015; 87(4):285-288.","DOI":"10.1002\/cyto.a.22643"},{"key":"64599","doi-asserted-by":"crossref","unstructured":"Chiron D, Bellanger C, Papin A. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016; 128(24):2808-2818.","DOI":"10.1182\/blood-2016-06-720490"},{"key":"64600","doi-asserted-by":"crossref","unstructured":"Charpentier E, Cornec M, Dumont S. 3\u2019 RNA sequencing for robust and low-cost gene expression profiling. Protoc Exch. 2021; 10:21203.","DOI":"10.21203\/rs.3.pex-1336\/v1"},{"key":"64601","doi-asserted-by":"crossref","unstructured":"Decombis S, Bellanger C, Le Bris Y. CARD11 gain of function upregulates BCL2A1 and promotes resistance to targeted therapies combination in B-cell lymphoma. Blood. 2023; 142(18):1543-1555.","DOI":"10.1182\/blood.2023020211"},{"key":"64602","doi-asserted-by":"crossref","unstructured":"Ferrer A, Salaverria I, Bosch F. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer. 2007; 109(12):2473-2480.","DOI":"10.1002\/cncr.22715"},{"key":"64603","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Thieblemont C, Oberic L. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017; 377(13):1250-1260.","DOI":"10.1056\/NEJMoa1701769"},{"key":"64604","doi-asserted-by":"crossref","unstructured":"Dempster JM, Rossen J, Kazachkova M. Extracting biological insights from the project achilles genome-scale CRISPR screens in cancer cell lines. BioRxiv. 2019.","DOI":"10.1101\/720243"},{"key":"64605","doi-asserted-by":"crossref","unstructured":"Chiron D, Dousset C, Brosseau C. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015; 6(11):8750.","DOI":"10.18632\/oncotarget.3275"},{"key":"64606","doi-asserted-by":"crossref","unstructured":"Thus YJ, De Rooij MFM, Swier N. Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation. Haematologica. 2022; 108(3):797-810.","DOI":"10.3324\/haematol.2022.281668"},{"key":"64607","doi-asserted-by":"crossref","unstructured":"Descamps G, Gomez-Bougie P, Tamburini J. The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. Br J Cancer. 2012; 106(10):1660-1667.","DOI":"10.1038\/bjc.2012.139"},{"key":"64608","doi-asserted-by":"crossref","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022 - A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022; 97(5):638-656.","DOI":"10.1002\/ajh.26523"},{"key":"64609","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Garcia D, Navarro A, Vald\u00e9s-Mas R. CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma. Blood. 2019; 133(9):940-951.","DOI":"10.1182\/blood-2018-07-862151"},{"key":"64610","doi-asserted-by":"crossref","unstructured":"Malarikova D, Berkova A, Obr A. Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy. Cancers. 2020; 12(8):2120.","DOI":"10.3390\/cancers12082120"},{"key":"64611","doi-asserted-by":"crossref","unstructured":"Martin P, Bartlett NL, Blum KA. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019; 133(11):1201-1204.","DOI":"10.1182\/blood-2018-11-886457"},{"key":"64612","doi-asserted-by":"crossref","unstructured":"Chiron D, Di Liberto M, Martin P. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014; 4(9):1022-1035.","DOI":"10.1158\/2159-8290.CD-14-0098"},{"key":"64613","doi-asserted-by":"crossref","unstructured":"Condorelli R, Spring L, O\u2019shaughnessy J. Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018; 29(3):640-645.","DOI":"10.1093\/annonc\/mdx784"},{"key":"64614","doi-asserted-by":"crossref","unstructured":"Malarikova D, Jorda R, Doln\u00edkov\u00e1 A. Cyclin-dependent kinase 4\/6 inhibitor palbociclib synergizes with BH3-mimetics in experimental models of relapsed\/refractory mantle cell lymphoma. Blood. 2022; 140(Suppl 1):5996-5997.","DOI":"10.1182\/blood-2022-168617"},{"key":"64615","doi-asserted-by":"crossref","unstructured":"Zhang L, Yao Y, Zhang S. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019; 11(491):eaau1167.","DOI":"10.1126\/scitranslmed.aau1167"},{"key":"64616","doi-asserted-by":"crossref","unstructured":"Thus YJ, Eldering E, Kater AP, Spaargaren M. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. Leukemia. 2022; 36(9):2165-2176.","DOI":"10.1038\/s41375-022-01627-9"},{"key":"64617","doi-asserted-by":"crossref","unstructured":"Prukova D, Andera L, Nahacka Z. Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res. 2019; 25(14):4455-4465.","DOI":"10.1158\/1078-0432.CCR-18-3275"},{"key":"64618","doi-asserted-by":"crossref","unstructured":"Rasmussen ML, Taneja N, Neininger AC. MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes. iScience. 2020; 23(4):101015.","DOI":"10.1016\/j.isci.2020.101015"},{"key":"64619","doi-asserted-by":"crossref","unstructured":"Zhao X, Ren Y, Lawlor M. BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models. Cancer Cell. 2019; 35(5):752-766.","DOI":"10.1016\/j.ccell.2019.04.005"},{"key":"64620","doi-asserted-by":"crossref","unstructured":"Zhao X, Bodo J, Chen R. Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma. EJHaem. 2020; 1(1):161-169.","DOI":"10.1002\/jha2.48"},{"key":"64621","doi-asserted-by":"crossref","unstructured":"Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science. 2013; 339(6125):1323-1328.","DOI":"10.1126\/science.1228792"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284345\/76624","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284345\/77349","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11464\/76624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:48Z","timestamp":1794045948000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284345","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}